MedTrace Logo

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

NCT04998981 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2025-05-23

No results posted yet for this study

Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG and Low HDL-C

Conditions

Interventions

DRUG

K-877 0.1 mg tablet

K-877 0.1 mg tablet x 2 twice daily

DRUG

Fenofibrate 200 mg capsule

Fenofibrate 200 mg capsule once daily

DRUG

Placebo tablet

Placebo tablet x 2 twice daily

DRUG

Placebo capsule

Placebo capsule once daily

DRUG

K-877 0.1 mg tablet

K-877 0.1 mg tablet twice daily

DRUG

Placebo tablet

Placebo tablet twice daily

Sponsors & Collaborators

  • Kowa Company, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2023-02-02
Completion
2023-02-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04998981 on ClinicalTrials.gov